ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD
ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD
Board Appoints Officers
董事會任命官員
ALLEN, Texas, March 25, 2024 /PRNewswire/ -- Enzolytics, Inc. (OTC PINK:ENZC) (" Enzolytics, Inc. (the "Company") On March 19th, 2024, a Special Meeting of the Shareholders of ENZC of which a quorum was present representing over 51% of the voting right of the company was held and new board of directors was elected.
德克薩斯州艾倫，2024年3月25日 /PRNewswire/ — Enzolytics, Inc.（場外交易代碼：ENZC）（” Enzolytics, Inc.（“公司”）2024年3月19日舉行了ENZC股東特別會議，該會議的法定人數佔公司表決權的51％以上，並選出了新的董事會。
This new board consists of Harry Zhabilov, Chairman of the Board; Dr. Lachezar Ivanov, and Dr. Gaurav Chandra. Dr. Ivanov and Harry Zhabilov have accepted their position as director, as of this date, Dr. Chandra has not. Immediately following this Special Shareholder Meeting, the New Board of Directors were noticed by Harry Zhabilov of a Special Called Meeting of the Board of Directors, which was held March 21, 2024 and a quorum was present. The new officers of the corporation were elected.
新董事會由董事會主席哈里·扎比洛夫、拉切扎爾·伊萬諾夫博士和高拉夫·錢德拉博士組成。伊萬諾夫博士和哈里·扎比洛夫已經接受了董事職位，但截至目前爲止，錢德拉博士尚未接受董事職位。在這次特別股東大會之後，哈里·扎比洛夫立即注意到新董事會召開了一次特別召集會議，該會議於 2024 年 3 月 21 日舉行，法定人數到場。公司新任高管當選。
The new executive officers appointed by the Board of Directors are Steven Sharabura – Chief Executive Officer, Diana Zhabilov – Chief Financial Officer, and Harry Zhabilov – Chief Science Officer. Dr Gaurav Chandra was duly noticed and nominated as an officer but declined the position of CEO. Dr. Chandra remains a director of the Company.
董事會任命的新執行官是首席執行官史蒂芬·沙拉布拉、首席財務官戴安娜·扎比洛夫和首席科學官哈里·扎比洛夫。高拉夫·錢德拉博士受到應有的關注並被提名爲高管，但拒絕擔任首席執行官一職。錢德拉博士仍然是公司的董事。
Steve Sharabura stated, "I am working with the board to formulate a new business strategy and identify acquisition targets. The Company will release additional information on our progress in the coming weeks."
史蒂夫·沙拉布拉表示：“我正在與董事會合作制定新的業務戰略並確定收購目標。該公司將在未來幾周內發佈有關我們進展的更多信息。”
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC.
安全港聲明：本新聞稿包含前瞻性陳述，涉及與財務預測、預算、里程碑時間表、臨床開發、監管批准以及Enzolytics, Inc.在向美國證券交易委員會提交的定期報告中不時描述的其他風險相關的風險和不確定性。
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to identify acquisition targets and formulate a business strategy for implementation. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
儘管Enzolytics, Inc.認爲其中包含的前瞻性陳述和基本假設是合理的，但任何假設都可能不準確，包括但不限於Enzolytics確定收購目標和制定實施業務戰略的能力。因此，無法保證本新聞稿中包含的前瞻性陳述將被證明是準確的。
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
此類前瞻性陳述基於當前的預期。它們涉及固有的風險和不確定性，包括可能延遲、轉移或改變任何陳述，並導致實際結果和結果與當前預期存在重大差異的因素。任何前瞻性陳述都無法保證。這些前瞻性陳述自本新聞稿發佈之日起作出。公司明確表示不打算或沒有義務更新前瞻性陳述或更新實際業績可能與前瞻性陳述中預測的結果不同的原因。
SOURCE Enzolytics, Inc.
來源 Enzolytics, Inc.
譯文內容由第三人軟體翻譯。